BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
BlossomHill Therapeutics has raised $84.0M in total funding. The most recent round was Series B. The last funding was announced in December 2025.
BlossomHill Therapeutics's investors include Vivo Capital, Cormorant Asset Management, Janus Henderson Investors, OrbiMed, BioTrack Capital.
BlossomHill Therapeutics is headquartered in San Diego, United States.
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
BlossomHill Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BlossomHill Therapeutics — Funding & Investors." VCBacked, December 10, 2025, https://www.vcbacked.co/company/blossomhill-therapeutics. Accessed September 15, 2026.
VCBacked. (2025). BlossomHill Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/blossomhill-therapeutics
{{cite web |title=BlossomHill Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/blossomhill-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated